Foundation Medicine to provide Novartis with genetic info for oncology programs

Friday, June 8, 2012 01:00 PM

Molecular information company Foundation Medicine has extended its pilot program with Novartis to provide comprehensive genomic analysis in support of Novartis' clinical oncology programs.

The pilot program, established 18 months, ago has generated very interesting data, and this type of tumor genomic profiling has become an essential component of Novartis' clinical trials. In the extended collaboration, Novartis plans to use Foundation's molecular information platform across many of its phase I and II oncology clinical programs. Novartis will run Foundation's comprehensive genomic profiling on most phase I and II clinical trial enrollees over the next three year, with the aim of accelerating the development of Novartis' broad portfolio of targeted cancer therapeutics and ultimately expand treatment options for patients.

"The comprehensive molecular assessment of Novartis' oncology clinical trial samples is expected to help to bring potentially lifesaving therapies to the right patients more quickly, and we expect that the wealth of molecular information will help fundamentally improve the way cancer is understood and treated," said Michael J. Pellini, M.D., president and CEO, Foundation Medicine. "We are pleased to see our collaboration mature into a significant relationship between Foundation Medicine and Novartis."

Foundation uses clinical-grade, next-generation sequencing to rapidly analyze hundreds of cancer-related genes from formalin-fixed, paraffin-embedded tumor samples in a CLIA-certified environment. Novartis plans to use these capabilities in an effort to align trial enrollment and outcome analysis with the genomic profile of individual patient tumors to drive development of new cancer treatments. Foundation may develop additional diagnostic products resulting from the Novartis collaboration.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs